Serena Nik-Zainal, MD, discusses study findings that could change the way treatment strategies for subgroups of patients with triple-negative breast cancer are evaluated.
A new study looked at the characteristics of diagnosed breast cancer cases in San Francisco.
Several clinicopathologic features of HER2-positive breast cancer patients were found to be associated with response to neoadjuvant therapy in a new study.
CancerNetwork® spoke with Dr. Peter Schmid about the KEYNOTE-522 trial.
Multigene testing for all woman diagnosed with breast cancer can be “extremely cost-effective.”
CancerNetwork® spoke with Dr. William Wood on the clinical risk of chemotherapy in early breast cancer.
A 21-gene assay is effective in guiding the use of adjuvant chemotherapy in patients with early breast cancer.
Dr. Rebecca Dent, oncologist at the National Cancer Center, Singapore, discusses the rationale for immunotherapy in early-stage breast cancer.
The results of the TAILORx trial went against previous ideas that breast cancer patients with a high Oncotype score who needed chemotherapy and endocrine therapy wouldn't fare well.
A new analysis found overall survival may be worse for some male breast cancer patients.